NCT00548353已完成1 期
A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 主要终点
- Safety in migraine patients
研究概览
简要总结
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-smoking male or female between 18 to 45 years of age
- •Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe
排除标准
- •Patient has any other medical conditions other than migraine
研究组 & 干预措施
1
Experimental
MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
干预措施: MK3207 (Drug)
结局指标
主要结局
Safety in migraine patients
时间窗: 12 Weeks
次要结局
- PK in migraine patients(12 Weeks)
研究者
相似试验
招募中
不适用
Post-marketing Clinical Trial of Elexir(Trigeminal Nerve Electrical Stimulator) for the Acute Treatment of MigraineMigraineNCT06170411Nu Eyne Co., Ltd.100
已完成
3 期
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)Episodic MigraineHeadacheHeadache, MigraineMigraineNCT06004388Click Therapeutics, Inc.110
已完成
3 期
Study to Test a Marketed Product in the Treatment of Migraine-associated NauseaMigraineNCT00250458Organon and Co346
招募中
不适用
Closed-loop RTMS for Short-term Migraine PreventionMigraine DisordersNCT06735768Brightmind.AI88
已完成
2 期
Efficacy and Safety of BGG492 in the Treatment of MigraineMigraineNCT00892203Novartis75